# Sub-Q Bionics Closes Pre-Seed Round, Targets Seed Funding, to Advance Implantable Lymphedema Solution for Breast Cancer Survivors

> financing · REPORTED · 2026-03-31

Sub-Q Bionics closed $1.5 million in pre-seed funding and signed a Mayo Clinic licensing agreement covering lymphatic surgery know-how, with plans to progress toward a first-in-human study for its implantable lymphatic drainage device designed specifically for breast cancer survivors living with lymphedema.

About Sub-Q Bionics: Sub-Q Bionics is a medical device company developing an implantable subcutaneous lymphatic drainage system to chronically manage lymphedema, a condition disproportionately affecting breast cancer survivors.

- Company: Sub-Q Bionics
- Sector: medical devices
- Primary source: https://www.biospace.com/press-releases/sub-q-bionics-closes-1-5m-pre-seed-round-to-advance-next-generation-solution-for-lymphedema-care

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.